Back to Browse Journals » Clinical Epidemiology » Volume 5 » Issue 1

Antidepressant exposure in pregnancy and risk of autism spectrum disorders

Authors Sørensen MJ, Grønborg TK, Christensen J, Parner ET, Vestergaard M, Schendel D, Pedersen LH

Published Date November 2013 Volume 2013:5(1) Pages 449—459

DOI http://dx.doi.org/10.2147/CLEP.S53009

Received 15 August 2013, Accepted 23 September 2013, Published 15 November 2013

Merete Juul Sørensen,1 Therese Koops Grønborg,2 Jakob Christensen,3,4 Erik Thorlund Parner,2 Mogens Vestergaard,5,6 Diana Schendel,7 Lars Henning Pedersen8,9

1Regional Centre of Child and Adolescent Psychiatry, Aarhus University Hospital, Risskov, Denmark; 2Department of Public Health, Section of Biostatistics, Aarhus University, Aarhus, Denmark; 3Department of Neurology, Aarhus University Hospital, Aarhus, Denmark; 4Department of Clinical Pharmacology, 5Department of Public Health, Section of General Practice, 6Research unit for General Practice, Aarhus University, Aarhus, Denmark; 7Centers for Disease Control and Prevention, Atlanta, GA, USA; 8Danish Epidemiological Science Centre, Institute of Public Health, 9Department of Obstetrics and Gynecology, Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark

Background: Both the use of antidepressant medication during pregnancy and the prevalence of autism spectrum disorder have increased during recent years. A causal link has recently been suggested, but the association may be confounded by the underlying indication for antidepressant use. We investigated the association between maternal use of antidepressant medication in pregnancy and autism, controlling for potential confounding factors.
Methods: We identified all children born alive in Denmark 1996–2006 (n=668,468) and their parents in the Danish Civil Registration System. We obtained information on the mother's prescriptions filled during pregnancy from the Danish National Prescription Registry, and on diagnoses of autism spectrum disorders in the children and diagnoses of psychiatric disorders in the parents from the Danish Psychiatric Central Register. In a cohort analysis, we estimated hazard ratios of autism spectrum disorders in children exposed to antidepressant medication during pregnancy compared with children who were not exposed, using Cox proportional hazards regression analysis. Furthermore, we estimated the risk for autism spectrum disorder in a sibling design.
Results: Children exposed prenatally to antidepressants had an adjusted hazard ratio of 1.5 (95% confidence interval [CI] 1.2–1.9) for autism spectrum disorder compared with unexposed children. Restricting the analysis to children of women with a diagnosis of affective disorder, the adjusted hazard ratio was 1.2 (95% CI 0.7–2.1), and the risk was further reduced when exposed children were compared with their unexposed siblings (adjusted hazard ratio 1.1; 95% CI 0.5–2.3).
Conclusion: After controlling for important confounding factors, there was no significant association between prenatal exposure to antidepressant medication and autism spectrum disorders in the offspring.

Keywords:
antidepressants, depression; autism, autism spectrum disorder, childhood autism, pregnancy

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Associated bone mineral density and obstructive sleep apnea in chronic obstructive pulmonary disease

Wang TY, Lo YL, Chou PC, Chung FT, Lin SM, Lin TY, Lin HC, Wang CH, Yu CT, Kuo HP

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:231-237

Published Date: 29 January 2015

Prospective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma

Fea AM, Belda JI, RÄ™kas M, Jünemann A, Chang L, Pablo L, Voskanyan L, Katz LJ

Clinical Ophthalmology 2014, 8:875-882

Published Date: 7 May 2014

Efficacy of micronutrient supplementation on skin aging and seasonal variation: a randomized, placebo-controlled, double-blind study

Fanian F, Mac-Mary S, Jeudy A, Lihoreau T, Messikh R, Ortonne JP, Sainthillier JM, Elkhyat A, Guichard A, Hejazi Kenari K, Humbert P

Clinical Interventions in Aging 2013, 8:1527-1537

Published Date: 14 November 2013

A role of cellular glutathione in the differential effects of iron oxide nanoparticles on antigen-specific T cell cytokine expression

Shen CC, Liang HJ, Wang CC, Liao MH, Jan TR

International Journal of Nanomedicine 2011, 6:2791-2798

Published Date: 8 November 2011

Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticles

Corem-Salkmon E, Ram Z, Daniels D, Perlstein B, Last D, Salomon S, Tamar G, Shneor R, Guez D, Margel S, Mardor Y

International Journal of Nanomedicine 2011, 6:1595-1602

Published Date: 3 August 2011

Applications of gold nanoparticles in cancer nanotechnology

Weibo Cai, Ting Gao, Hao Hong, Jiangtao Sun

Nanotechnology, Science and Applications 2008, 1:17-32

Published Date: 19 September 2008